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Introduction: In the United States, the total number of confirmed 
reported cases of Covid-19 had reached 6.45 million with a total death 
of 193, 246 as of Sept 6, 2020. Significant efforts have been invested 
to flatten the curve and control new cases appearing in the socie-
ties. Meanwhile, the governments has imposed a lockdown with the 
objective of controlling the transmission of the virus. The re-opening 
of societies is challenging and might involve threats, many of them 
remain unseen. 
Methods: We present here the validation of a Lateral Flow Immuno-
chromatographic Assay in comparison with RT-PCR and describe a 
dynamic scenario to un-locking and re-opening societies using an 
evidence-based design, suggested by an algorithm of screening using 
RT-PCR and antibodies in a large population.
Results and Conclusion: In the absence of highly reliable vaccine and/
or treatment for Covid-19, the decision to go back to work or stay 
at home remains controversial and risky. Controversial because our 
limited knowledge of the virus and risky in view of the uncertainty of 
acquired immunity. Attempts based on multi-analytical approaches, 
such as the algorithm presented here, are required for a better ma-
nagement and a more flexible fine tuning of re-opening societies.
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Introduction
As of September 6, 2020, the virus SARS-Cov2 had resulted in more than 
27,282,417 infections and 887,277 deaths worldwide. The disease caused 
by this virus, COVID-19 has now been reported on every continent. In the 
United States, the total number of confirmed reported cases of Covid-19 
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had reached 6.45 million with a total death of 193, 
246 and a total confirmed recoveries of 3,725,970 
cases (https://worldometers.information). The medi-
cal, social, and economic impacts of this pandemic 
have been so far unexpectedly devastating for the 
whole world. The main interest of the countries, as 
recommended by epidemiologists and specialists, 
has been for the time being how to flatten the cur-
ve and control new cases appearing in the societies. 
Meanwhile, governments are/have been imposing 
a lockdown in their countries with the objective of 
controlling better the transmission to non-infected 
people, and therefore, enable hospitals and health 
authorities to provide an optimal health care in view 
of the severe limitation and shortage of reanima-
tion material and Personal Protective Equipment. 
Attempts to find the “best” available drug have 
identified so far some molecules including Hydro-
xycholoroquine, Remdisivir, and others [1, 2]. On the 
other hand, researchers in different countries are 
working hard for thedevelopment of new vaccines 
[3, 4], however, a successful vaccine might not be 
available before the year 2021.
Physical (social) distancing has been so far consi-
dered as the only affordable measure despite many 
objections and incompliances. The main purpose of 
a lockdownis to reduce the transmission and there-
fore, the reproduction of the virus, in other terms, 
to reduce the number of people each confirmed 
case infects [5, 6]
Lockdown and confinement aim to reverse epide-
mic growth, reducing therefore the case numbers 
to low levels by social distancing [5]. In absence of 
a strict lockdown that creates quarantines sepa-
rating people who are vulnerable to the infection 
and people who are not infected from those who 
harbor the virus and shedding it in their respiratory 
secretions, one can expect a very high rate of mor-
tality. However, an end to lockdown is many weeks 
away for some nations, but decisions on how to 
do it need to be made now so preparations can be 
made and communicated clearly. 
Being an emergency measure, the lockdown is 
only transitory and “Un-locking” countries is a must 
regardless how long it would take. It needs to be 
done carefully with a strict strategy that takes into 
account the epidemiologic characteristic of the in-
fection, the socio-economic needs of the society, as 
well as many other cultural, economic, and health 
related details [6] Such strategies should make use 
of current technologies using contact tracing, pro-
tective gear and aggressive testing of post-virus 
immunity. Obviously, unlocking without a proper 
strategy might have serious and severe drawbacks, 
where the most likely outcome might be that the 
epidemic starts again. This should be clearly distin-
guished from a second wave that normally appears 
after the re-opening of societies; however, if a well-
controlled re-opening is done, the second wave of 
viral infection would be much less aggressive and 
much better handled.
Here, we describe and proposes a dynamic scena-
rio to un-locking and re-openingsocieties using an 
evidence-based design, suggested by an algorithm 
of screening using RT-PCR and antibodies in a large 
population of Saginaw-Michigan.
Michigan Health Clinics, a multispecialty health 
care provider in the Great Lakes Bay Region, has 
been actively involved in providing Covid-19 tes-
ting to the citizens of Michigan since the beginning 
of the crisis. Lately, our services were extended in 
a significant way to provide large Drive-In testing 
of SARS-Cov2 of the citizens of Saginaw; so far, 
the screening reached 1572 people. The algorithm 
of testing is based on the latest developments in 
SARS-Cov2 detection using Real Time-Polymerase 
Chain Reaction (RT-PCR), as well as serological de-
tection of antibodies against the virus (IgG and 
IgM) by Lateral Flow Immunochromatographic As-
says.
The algorithm of screening is based on the dia-
gram in Figure 1. Briefly, a screening using Lateral 
Flow Immuno-chromatographic Assay is performed 
on the plasma of all symptomatic and asymptoma-
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tic people. The test was validated in our labs with 
a sensitivity and specificity rates were determined 
as compared to RT-PCR testing (Section III below). 
As shown in this algorithm, depending on the re-
sults of IgM and IgG, the next step of testing is 
decided. RT-PCR (according to the instructions of 
CDC) is performed on nasopharyngeal swab from 
all patients who tested positive for at least one the 
antibodies. Symptomatic patients were also tested 
for Influenza A, Influenza B, RSV, and hMPV using 
Helicase Dependent Amplification Assays (Solana- 
Quidel, USA). 
Material and Methods
Lateral Flow Immunochromatographic 
Assay (Healgen kit) and RT-PCR testing
The detection of Immunoglobulins (M and G) uses 
the principle of immunochromatography: the sepa-
ration of components in a mixture through a me-
dium using capillary force and the specific and rapid 
binding of an antibody to its antigen. The detection 
of each antibody is performed on a separate cas-
sette. Each cassette is a dry medium that has been 
coated separately with novel coronavirus N protein 
(“T” test line) and goat anti-chicken IgY antibody 
(“C” control line). Two free colloidal gold-labeled 
antibodies, mouse anti-human IgM (mIgM) and 
chicken IgY, are in the release pad section (S), also 
Two free colloidal gold-labeled antibodies, mouse 
anti-human IgG (mIgG) and chicken IgY, are in the 
release pad section (S). Once diluted serum, plasma, 
or whole blood is applied to the release pad section, 
the mIgM or mIgG antibody will bind to coronavi-
rus IgM antibodies if they are present, forming an 
IgM-IgM complex. The sample and antibodies will 
then move across the cassette’s medium via capi-
llary action. If coronavirus IgM antibody is present 
in the sample, the test line (T) will be bound by the 
IgM-IgM complex and develop color. If there is no 
coronavirus IgM antibody in the sample, free mIgM 
will not bind to the test line (T) and no color will 
develop. The free chicken IgY antibody will bind to 
the control line (C); this control line should be visible 
after the detection step as this confirms that the kit 
is working properly. 
Figure 1: Asymptomatic and symptomatic Patients.
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Sample
EDTA plasma was used the preferred specimen. 
Specimens not centrifuged and tested within two 
hours of collection were stored at 2-8°C for up to 
7 days. 
Reagents
SARS-Cov2 IgM/IgG Antibody Detection kit from 
Healgen was used. The detection cassettes inclu-
ded: Novel coronavirus N protein, Goat anti-chicken 
IgY antibody, Colloidal gold-labeled mouse anti-hu-
man IgM antibody and mouse anti-human IgG (S), 
and Plastic pipette dropper
Description of Test and Reporting of Results
The LFIA test was performed according to the 
manufacturer’s instruction and the results were 
interpreted either as Negative IgM, Negative IgG: 
Negative results: No evidence of an increase in hu-
man IgM and IgG production against SARS-Cov2. 
A negative or non-reactive result might indicate a 
state of no infection or an incubation period of the 
virus. In case of suspicious exposure, the patient 
should be advised to repeat the test in 7 to 10 
days. A negative result can also be due to a delayed 
immune response by the patient.
A Positive IgM, Negative IgG or Non-reactive: 
This result can indicate an early stage of SARS-
Cov2 infection. The absence of IgG indicates that 
the patient did not develop acquired immunity 
yet.
A. Positive IgM, Positive IgG. IgM positive and 
IgG positive: This result suggests either an ac-
tive or an early recovery stage of the infection 
with SARS-Cov2.
B. Negative IgM, Positive IgG. IgM negative 
and IgG positive: This result indicates a late 
stage or a past infection with SARS-Cov2. This 
suggests that an acquired immunity has deve-
loped to the virus.
For molecular testing, a naso-pharyngeal 
swab was obtained from the same patient
RT-PCR experiments were not performed in our lab, 
they were sent to a reference lab and results were 
communicated within 24 hours.
Performance evaluation of LFIA
A 90 whole blood samples were tested after the 
approval of the Institution Review Board (IRB). The 
blood samples were transferred from tubes with 
anticoagulant (EDTA) previously collected from pa-
tients tested for Covid19 with PCR. Since our in-
tention was to perform the test on plasma from 
patients, our validation procedure addressed only 
plasma samples. No validation was done concerning 
serum, whole blood, or capillary blood samples.
Sensitivity and specificity determination
Both sensitivity and Specificity were determined as 
per the following formulas: 
Sensitivity %= 100 x [True Positive/(True Positive 
+ False Negative)]
Specificity % = 100 x [True negative / (True Ne-
gative + False Positive)].
Accuracy and Limit of detection (LoD)
Three serial dilutions from three different patients’ 
plasma were prepared separately. The dilution in-
terval from one dilution to another was the double 
leading to decreasing concentrations by half. 
Detection of antibodies was performed 
on all the dilutions
Intra-assay validation (Intra-assay 
Repeatability)
Eight plasma samples were run in 5 repetitions each. 
The table does not show the Means, Standard De-
viations, and Coefficients of Variation because the 
test is either positive or negative
Inter-assay precision (Inter-assay 
Repeatability)
Inter-assayassay precision shows the reprodu-
cibility between assays done on different days. 
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Inter-assay precision is typically <10%. This en-
sures the results obtained will be consistent over 
time and between kits. The table does not show 
the Means, Standard Deviations, and Coefficients 
of Variation because the test is either positive or 
negative
A.  Cross Reactivity Assays was evaluated for IgM 
and IgG SARS-Cov2 detection rapid test using 
plasma samples from patients with documen-
ted antibodies against the below listed patho-
gens.
B.  Class Specificity: Class specificity for Human 
IgM (0.4 mg/ml of Human IgM Purified Im-
munoglobulin- Biorad) to cross react and 
produce false positive results for IgG was 
evaluated using 5 Patients’ plasma with IgG 
negative. Class specificity of Human IgG (8 
mg/ml of Natural Human IgG -Biorad) to cross 
react and produce false positive results for 
IgM was evaluated using 5 Patients’ plasma 
with IgM negative. Each sample was tested in 
duplicate. The ability of Human IgM 0.4 mg/
ml and Human IgG 8 mg/ml to compete and 
produce false negative results for IgM or IgG 
was evaluated using 5 patients’ plasma (IgM 
positive IgG positive). Each sample was tested 
in duplicate
C.  Potentially interfering substances were tested 
after preparing low titer SARS-CoV2 antibody 
positive serum samples and SARS-Cov2 an-
tibody negative serum samples. Aliquots of 
both preparations were spiked with potentia-
lly interfering substances to approximate the 
indicated concentrations and tested triplica-
tes. 
Testing Algorithm
A testing algorithm was developed taking into ac-
count the high sensitivity and specificity of the LFIA 
in conjunction with the PCR results. 
Results
Clinical evaluation
Clinical Performance: Sensitivity and 
Specificity 
In Table 1 results show limitation of testing 90 
samples (43 positive samples and 47 Negative 
samples by RT-PCR). Clinical Performance: The 
conclusion is as below. A very good coincidence 
rate was found between the two methods. Po-
sitive coincidence rate is 90.7%, negative coinci-
dence rate is 97.8%, and total coincidence rate is 
94.4%. Table 2 & 5.
Table 1.  Sensitivity and specificity of the tested com-
bined IgM/IgG determination method ver-





+ 39 1 40
- 4 46 50
Total 43 47 90
Clinical Accuracy of Kit 2 alone on a selection of 73 
Positive and 52 Negative patients
Sensitivity 90.7%
Specificity 97.8%
Agreement, Total Agreement 94.4%
Table 2.  Sensitivity and specificity of the separa-
te and combined IgM/IgG determination 
method versus the PCR method. Sensitivi-
ty and specificity of tested antibodies, and 
accuracy and Limit of detection (LoD) for 
IgM and IgG.
Domains/Facets
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Table 3. Dilutions of the initial plasma*.
D 3 D0 D1 D2 D3 D4 D5 D6
 [ ] 1 0.5 D0 0.25 D0 0.125 D0 0.062 D0 0.031 D0 0.016 D0
Vol Diluent mcl 0 50 50 50 50 50 50
Vol trasf mcl 0 50 50 50 50 50 50
Band Control + + + + + + -
Band IgM + + + - - - -
Band IgG + + + + + + -
*: LoD for IgM = 0.25 D0, LoD for IgG= 0.031 D0.
Table 4. Dilutions of the initial plasma*.
D 29 D0 D1 D2 D3 D4 D5 D6
 [ ] 1 0.5 D0 0.25 D0 0.125 D0 0.062 D0 0.031 D0 0.016 D0
Vol Diluent mcl 0 50 50 50 50 50 50
Vol trasf mcl 0 50 50 50 50 50 50
Band Control + + + + + + -
Band IgM + + + - - - -
Band IgG + + + + + + -
*: LoD for IgM = 0.25 D0, LoD for IgG= 0.031 D0.
Table 5. Dilutions of the initial plasma*.
D 99 D0 D1 D2 D3 D4 D5 D6
 [ ] 1 0.5 D0 0.25 D0 0.125 D0 0.062 D0 0.031 D0 0.016 D0
Vol Diluent mcl 0 50 50 50 50 50 50
Vol trasf mcl 0 50 50 50 50 50 50
Band Control + + + + + + -
Band IgM + + + - - - -
Band IgG + + + + + + -
*: LoD for IgM = 0.25 D0, LoD for IgG= 0.031 D0.
Intra-assay validation
The Intra-assay validation shows the reproducibility 
between tubes within one testing time. Data resul-
ting from intra-assay validation helps ensure that 
samples run in different tubes of the same expe-
riment will give comparable results. Eight plasma 
samples were run in 5 repetitions each. All tests 
gave the same results in 5 different tubes and cas-
settes as show in Table 6.
Inter-assay precision (Inter-assay 
Repeatability)
Inter-assay precision shows the reproducibility bet-
ween assays done on different days. Inter-assay 
precision is typically <10%. This ensures the results 
obtained will be consistent over time and between 
kits. All tests gave the same results over 5 conse-
cutive days Table 7.
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Table 6.  Intra-assay experiment showing the repro-
ducibility between tubes within one testing 
time.
67 71 1 86 22 49 44 125
IgM
T1 P P N P N P N N
T2 P P N P N P N N
T3 P P N P N P N N
T4 P P N P N P N N
T5 P P N P N P N N
IgG
T1 P P N P N P N N
T2 P P N P N P N N
T3 P P N P N P N N
T4 P P N P N P N N
T5 P P N P N P N N
Table 7.  Inter-assay precision showing the reprodu-
cibility between assays done on different 
days.
Day 67 71 1 86 22 49 44 125
IgM
1 P P N P N P N N
2 P P N P N P N N
3 P P N P N P N N
4 P P N P N P N N
5 P P N P N P N N
IgG
1 P P N P N P N N
2 P P N P N P N N
3 P P N P N P N N
4 P P N P N P N N
5 P P N P N P N N
Cross Reactivity Assays
No false positivity was found for IgM or IgG with 
the following organisms.
Human Coronavirus 229 E (alpha coronavirus)- 5 
patients, Human Coronavirus NL63 (alpha corona-
virus)- 5 patients, Human Coronavirus HKU1 (beta 
coronavirus)- 5 patients, Respiratory Syncytial Virus 
(IgG and IgM)- 5 patients
Human Coronavirus NL63+RSV- 2 patients, Hu-
man Coronavirus 229+RSV – 2 patients
Human Metapneumovirus (hMPV)- 5 patients, 
Parainfluenza virus (1, 3)- 5 patients, Influenza A 
(IgG and IgM)- 5 patients, Influenza B (IgG and 
IgM)- 5 patients, Hepatitis C Virus (IgG and IgM)- 4 
patients, Hepatitis B Virus (IgG and IgM)- 4 patients, 
Haemophilus influenzae (IgG and IgM)- 5 patients, 
Chlamydia pneumoniae- 3 patients, HPV- 5 pa-
tients, HIV- 5 patients
Class Specificity Assays
We evaluated the potential for:
• Human IgM to cross react and produce false 
positive results for IgG: No false positivity for 
IgG was detected
• Human IgG to cross react and produce false 
positive results for IgM: No false positivity for 
IgM was detected
• Human IgM and Human IgG to compete and 
produce false negative results for IgM or IgG: 
No false negativity for IgM or IgG was de-
tected
Potentially interfering substances
We prepared 1- low titer SARS-CoV2 antibody po-
sitive serum samples and 2- SARS-Cov2 antibody 
negative serum samples. We spiked aliquots of both 
preparations with one of the below substances to 
approximate the indicated concentrations and tes-
ted triplicates. No false positivity or false negativity 
was found with the following:
Hemoglobin (10 to 20 mg/mL), Bilirubin Con-
jugated <1 mg/mL, Bilirubin Unconjugated <1 
mg/mL, Ciprofloxacin 200 mg/L, Cefotaxime 
500 mg/L, Meropenem 200 mg/L, Imipenem 
200 mg/L, Amikacin 10 mg/L, Amphotericin B 
200 mg/L.
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The Testing Algorithm
This algorithm of screening is recommended when 
screening large populations for many reasons: 
1. Its high ability to assess whether the patient 
is infected or not and what is the state of the 
immune response (Figure 2)
2. It confirms any serology positive result by the 
use of RT-PCR, which is a sophisticated and 
expensive technique requiring highly trained 
personnel (Figure 3)
3. It saves RT-PCR material for needy cases since 
the algorithm does not recommend screening 
all patients using RT-PCR. In this context, spa-
ring molecular kits is a must in such a scenario 
of pandemic in view of the high demand and 
shortage in availability (Figure 4)
Discussion
Arguably, the detection of immunoglobulins IgM 
and IgG has been questioned by many scientists and 
practitioners in view of the false negative results it 
can engender, the false positive results being much 
less do not pose a serious threat [7, 8]. Serology 
looks for antibodies against SARS-Cov2 in the blood 
to determine if there has been an infection in the 
past. Antibodies are formed by the body to fight off 
infections. IgM is the first antibody that is formed 
against a germ, so it appears on tests first, usually 
within 1-2 weeks depending on the immunity of 
the patient. The body thenforms IgG, which ap-
pears on tests about 2 weeks after theillness starts. 
IgM usually disappears from the blood within afew 
months, but IgG can last for years [9]. In the “Tes-
ting Blueprint, Opening Up America Again” recently 
Figure 2.
The InTernaTIonal arabIc Journal of anTImIcrobIal agenTs 
ISSN: 2174-9094
2020
Vol. 10 No. 3:3
doi: 10.3823/850
© Under License of Creative Commons Attribution 3.0 License 9
Figure 3.
Figure 4.
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issued [10]. The white house puts a plan for States 
to “maximize testing capability and protect health 
and safety during this pandemic and beyond”. In 
this document, it was demonstrated that the use 
of two antibody tests rather than one dramatically 
improves the predictive value of a testing program, 
particularly in low prevalence environments. Higher 
positive predictive values (PPV) indicate that you 
most likely had the disease and produced antibodies 
in response. Higher negative predictive values (NPV) 
indicate you do not have antibodies and most likely 
have not had the disease [10].
The RT-PCR looks for the virus itself in the nose, 
throat, or other areas in the respiratory tract to de-
termine if there is an active infection with SARS-
Cov2 [11]. A positive PCR test suggests that the per-
son being tested has an active COVID-19 infection. 
PCR testing only helps determine whether a person 
has an active infection at the time of testing. Un-
fortunately, it does not help determine who had an 
infection in the past. It also does not help determine 
which people who have been exposed to COVID-19 
will develop active infection during the 2 weeks af-
ter exposure. In some people, the virus can only be 
found by PCR for a few days at the beginning of 
the infection, so the test might not find the virus if 
the swab is taken more than a few days after the 
illness starts.
All this led us to adopt a algorithm combining 
both RT-PCR and Serology testing in order to make 
a decision about past/present infection of indivi-
duals in large populations.
This screening algorithm might have 2 main li-
mitations: 
1. people who test negative for IgM and IgG are 
not tested by PCR, and this decisionis based on 
the high sensitivity of the technique (86.9%), 
this might entail however the possibility for False 
Negatives. False positivity of the serology tech-
nique was considered very rare in view of the 
high associated specificity as validated by our lab 
(96.2%). In addition, the combination of 2 Late-
ral Flow Immunochromatographic Assays for the 
detection of immunoglobulins greatly improved 
sensitivity as well as Positive and Negative Pre-
dicted Values generated by this testing. 
2. The PCR results might be erroneous sometimes 
giving rise to False Positive or False Negative re-
sults. Taking into account that re-opening socie-
ties cannot happen in absolute absence of the 
virus, entailing that the use of Personal Protecti-
ve Equipment should not be discontinued during 
this process where a minimum of risk can exist, 
these two limitations were considered within the 
calculated risk. The below algorithm appears to 
be a more logical and feasible scenario to tes-
ting all the population using RT-PCR. This latter 
is practically not feasible in view of the price and 
severe shortage of molecular materialconsidered 
precious for hospitalized patients.
Socialize or Quarantine: the process
Obviously, people cannot be quarantined forever, 
not even for a very long time. The drawbacks of 
lockdown can lead to several challenges of diffe-
rent natures: economic, psychologic, financial, so-
cial, etc., at both individual as well as national levels 
[5]. Therefore, after the curve is “flattened”, socie-
ties are expected to re-open and become able to 
“resuscitate” from the pandemic. In absence of an 
effective vaccine, acquiring Herd Immunity is not 
easy [6]. Such immunity is in general based on in-
creasing the number of IgG seropositive people in 
a specific society by active/passive artificial/natural 
immunization. The re-opening can follow different 
scenarios that surely depend on the epidemiolo-
gic traits of the pandemic, the biologic features of 
the virus, mainly its mechanisms of transmission, in 
addition to several other social and economic para-
meters [12]. Taking all this into account, we deve-
loped aninteractive diagram allowing a progressive 
polyphasic passage from the state of Quarantine to 
the state of Open-Society in a smooth, slow, and 
safer way. This passage is based on a calculated 
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estimation of the “Transmission potential” of the 
individual and a subsequent decision to “Quaranti-
ne” or “Inject” in the society. This evidence-based 
decision is made in the light of the SARS-Cov-2 
detection in a nasopharyngeal swab by RT-PCR, and 
IgM/IgG detection in the patients’ blood. Below, 
Figures 2, 3, and 4 illustrate a schematic description 
of this progressive decision making process.
One important information that the detection of 
the virus cannot provide, is the state of immuni-
ty of the patient, for this, serology testing is the 
only data that could tell whether the patient has 
acquired immunity or not. As well as any diagnos-
tic investigation, the detection of immunoglobulins 
has limitations. For example, the body might not 
produce enough antibodies before 3 to 5 days of 
symptomatology or 5 to 7 days of viral entry in 
the human tissues, therefore, relying on serologic 
tests too soon after infection can yield false nega-
tive results. For this, the serologic testing should 
not be used alone as a primary method of diag-
nosing COVID-19 in an acutely ill patient. When a 
patient is symptomatic and experiencing the grea-
test viral replication, a molecular test is most useful 
for detecting the virus and determining a course of 
treatment.
Evidence-based Reopening of societies
Phases: After massive testing of the population, 
people can be categorized in 4 stages: 
1. Stage 0 Very low Risk for Transmission (IgG+/
IgM-/PCR- and IgG-/IgM-)
2. Stage 1 Risk of Infectiousness (IgG+/IgM+/
PCR-, and IgG-/IgM+/PCR-)
3. Stage 2 Risk of Infectiousness (IgG+/IgM+/
PCR+, and IgG+/IgM+/PCR+)
4. Stage 3 Risk of Infectiousness (IgG-/IgM+/
PCR+)
The majority of people testing negative for both 
IgM and IgG are considered virus-free, and therefo-
re, safe in terms of disease transmission to others. 
However, if exposed to the virus, they might get 
infected and develop the disease. Subsequently, to 
keep them safe, the only category of patients that 
can interact with them are those patients who are 
IgG seropositive, meaning those who already deve-
loped IgGs and are not anymore positive of SARS-
Cov2 by RT-PCR. There is however a risk in this 
combination, this risk is represented by the possible 
False negativity of IgM and IgG. Working with lar-
ge populations cannot secure an absolute 100% of 
safety. The issue here is to bring the calculated risk 
as minimal as possible. Re-opening the society with 
only people who are IgG seropositivewill not bring 
a considerably high number of people to work and 
normal life, at least, not high enough for the regular 
functioning of the society. On the other hand, the-
low rate of False negativitycan create a risk to the 
non-immune population, however, a manageable 
risk that can be controlled by the hospitals; such a 
risk is not expected to overwhelm the hospitals and 
health sector.
Phase 1
During this phase, Only people in Stage 0 are 
allowed to work. This will allow a good percentage 
of people to get back to work in a “safe” environ-
ment. The remaining people will remain in confine-
ment until a sero-conversion is detected. When this 
happens they will be allowed to get back to work, 
always in a re-opening society respecting physical 
distancing ant use of mask. A Re-testing shall be 
performed after 7 days, then after 14 days, accor-
dingly, people in Stage 1 will be allowed to go back 
to society when they convert into Stage 0.
Phase 2
During this phase, the number of people going back 
to work is expected to keep increasing while less 
people will be quarantined as shown here below. 
Testing and Re-testing will continue after 7 and 14 
days as described for phase 1. The risk factors des-
cribed in phase 1 remain the same in this phase 2.
Phase 3
During this phase, the number of people going back 
to work will keep increasing while less people will 
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be quarantined as shown here below. Testing and 
Re-testing will continue after 7 and 14 days as des-
cribed for phases 1 and 2. The risk factors described 
in phases 1 and 2 remain the same here.
Special considerations
Some populations will not be able to go back to 
normal life before a longer time, at least not be-
fore a suitable vaccine is developed. Among these, 
people under high risk of infection, patients with 
chronic diseases, elderly, etc. Patients testing positi-
ve for SARS-Cov2 need also to remain quarantined 
until the microbiological recovery is achieved.
In addition, returning to the normal life should 
be done wisely and progressively, in other terms, 
people should consider that risk remains there and 
should deal with each other on the basis of “possi-
bly infectious”. The already established rules, mainly 
wearing a mask, avoiding large social gatherings 
and events, keeping physical distance, etc. need 
to be respected and should not be ignored befo-
re a successful vaccine is made available. Time will 
be a major factor in unveiling the post-pandemic 
consequences, it is important to bear in mind that 
“Survival if for the fittest”, in this case fitness can 
be provided by immunity rather than confinement. 
Governments, municipalities, and other authorities 
have the obligation of controlling and overseeing 
the re-opening of societies, imposing therefore a 
progressively increasing capacities over the different 
phases in restaurants, indoor ay outdoor activities, 
social gatherings, back-to-school, etc.
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